← FDA DRUG APPROVALS
FDA NDA · NDA020802
EXCEDRIN MIGRAINE GELTABS
acetaminophen, asprin, caffeine
Sponsor: HALEON US HOLDINGS
APPLICATION
NDA020802
TYPE
NDA
ORIGINAL APPROVAL
1998-01-14
LATEST ACTION
2023-05-15
ROUTE
ORAL
DOSAGE FORM
TABLET
MARKETING STATUS
Over-the-counter
Products
EXCEDRIN (MIGRAINE RELIEF) · ReferenceOver-the-counter
ACETAMINOPHEN 250MG, ASPIRIN 250MG, CAFFEINE 65MG · TABLET · ORAL
Approval history
2017-09-13Manufacturing (CMC) · Supplement 30 · standardAP
2016-04-29Manufacturing (CMC) · Supplement 28 · standardAP
2016-01-28Manufacturing (CMC) · Supplement 27 · standardAP
2015-11-17Manufacturing (CMC) · Supplement 26 · standardAP
2014-07-30Manufacturing (CMC) · Supplement 25 · standardAP
2002-04-19Manufacturing (CMC) · Supplement 7 · standardAP
2000-10-10Manufacturing (CMC) · Supplement 6 · standardAP
2000-09-07Labeling · Supplement 4 · standardAP
2000-04-26Manufacturing (CMC) · Supplement 5 · standardAP
1999-08-20Manufacturing (CMC) · Supplement 3 · standardAP
1998-10-22Manufacturing (CMC) · Supplement 1 · standardAP
Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.
Weekly Briefing
Read a past issue →Get the Weekly GxP Briefing
Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.